Table 2.

Preclinical strategy of nanoparticle-based NK cell therapy.

Year	Cell Source	Nanoparticle	Tumor Type	Combination	Ref.
2014	Endogenous	Lipid-calcium-phosphate nanoparticle and liposome-protamine-hyaluronic acid nanoparticle	Melanoma	siTGF-β	[64]
2012	Endogenous	Liposomal polymeric gel	Metastatic melanoma	TGF-β inhibitor (SB505124)	[65]
2020	NK-92	Nanoemulsion	Triple negative breast cancer	Selenocysteine, TGF-β inhibitor (SB505124)	[66]
2017	Endogenous	Chitosan nanoparticle	Colon cancer	NKG2D, IL-21	[67]
2018	Endogenous	DOTAP:cholesterol nanovesicle	Lung cancer	TUSC2 gene, anti-PD-1	[68]
2019	Endogenous	Lipid nanoparticle	Triple negative breast cancer	cdGMP, monophosphoryl lipid A	[69]
2017	Endogenous	PLGA microsphere	Hepatocellular carcinoma	IFN-γ, Transcatheter intra-arterial infusion	[70]
2012	NK-92MI	Magnetic nanoparticle	B cell lymphoma	External magnetic field	[71]
2018	Human primary NK cell	Magnetic nanoparticle	Non-small cell lung cancer	External magnetic field	[55]
2015	Mouse primary NK cell	TRAIL-coated liposome	Lymph node metastatic cancer	TRAIL, anti-NK1.1	[72]
2020	NK-92MI	Cationic magnetic nanoparticle	Triple negative breast cancer	-	[73]
2019	Human primary NK cell	Immunomodulating nanoparticle	Triple negative breast cancer	phenylboronic acid, IgG	[74]
2020	Mouse primary NK cell	Trifunctional PLGA nanoparticle	EGFR positive solid tumor	Epirubicin	[75]